Special Promotion on Full-length Popular Drug Target Proteins!

Struggling to find full-length drug target proteins with bioactivity? Look no further! DIMA Biotech is excited to announce a special promotion on our full-length multi-pass transmembrane proteins, featuring Virus-like particles (VLPs) and membrane nanoparticles (MNPs). For a limited time, we’re offering select VLP and MNP proteins at a special price of $299 for a 50 […]

CDH17: A Target for Diverse Solid Tumor Therapies—Will It Lead to Significant Breakthroughs in Cancer Treatment?

In March 2022, a study published in Nature Cancer highlighted Cadherin 17 (CDH17) as an ideal target for chimeric antigen receptor (CAR) T-cell therapy in gastrointestinal tumors (including gastric cancer, pancreatic cancer, and colorectal cancer) and neuroendocrine tumors (NETs). CDH17 swiftly gained attention across major news platforms, providing fresh insights into tumor-associated antigens and the […]

Tumor Immune Target – Claudin18.2

Since Ganymed unveiled the efficacy data of Zolbetuximab (IMAB362), the anti-Claudin18.2 monoclonal antibody, for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJ) at the 2016 ASCO conference, Claudin18.2 has emerged as a focal point for pharmaceutical companies eager to advance therapeutic options. These companies explore various technological routes, including monoclonal antibodies, bispecific antibodies, […]